Read by QxMD icon Read

European Journal of Haematology

Susanna Gassiot, Cristina Motlló, Inuska Llombart, Mireia Morgades, Yolanda González, Montse Garcia-Caro, Josep-Maria Ribera, Albert Oriol
OBJECTIVE: Clinical trials for multiple myeloma patients using novel agent-based regimens before autologous stem cell transplantation (SCT) have shown improvement in response rates and progression-free survival (PFS), however they have failed to identify a significant overall survival (OS) benefit. The aim of this study was to analyze the potential impact of initial induction on the feasibility and outcome of subsequent treatment lines in a real clinical practice setting. METHODS: Consecutive multiple myeloma patients less than 70 years of age diagnosed between 1999 and 2009 were prospectively registered and classified as having received conventional chemotherapy induction regimens with new agents available at relapse (CC cohort, 89 patients) or as treated with novel agents upfront (NA cohort, 65 patients)...
February 16, 2017: European Journal of Haematology
Pilar de la Puente, Abdel Kareem Azab
Multiple myeloma (MM) is a hematological malignancy that remains incurable, with relapse rates greater than 90%. The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. The emphasis in cancer treatment has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted and rationally designed therapies showing greater efficacy and fewer side effects. Traditional chemotherapy has shown several disadvantages such as lack of targeting capabilities, systemic toxicity and side effects; low therapeutic index, as well as, most anticancer drugs have poor water solubility...
February 16, 2017: European Journal of Haematology
Maria Mainou, Anastasia-Vasiliki Madenidou, Aris Liakos, Paschalis Paschos, Thomas Karagiannis, Eleni Bekiari, Efthymia Vlachaki, Zhen Wang, Mohammad Hassan Murad, Shaji Kumar, Apostolos Tsapas
OBJECTIVES: We performed a systematic review and meta-regression analysis of randomized control trials to investigate the association between response to initial treatment and survival outcomes in patients with newly diagnosed multiple myeloma (MM). METHODS: Response outcomes included complete response (CR) and the combined outcome of CR or Very Good Partial Response (VGPR), while survival outcomes were overall survival (OS) and progression free survival (PFS). We used random effects meta-regression models and conducted sensitivity analyses based on definition of CR and study quality...
February 8, 2017: European Journal of Haematology
Carmen P Montano Almendras, Christian S Thudium, Henrik Löfvall, Ilana Moscatelli, Axel Schambach, Kim Henriksen, Johan Richter
OBJECTIVES: Here we tested the hypothesis that human M-CSF (hM-CSF) overexpressed in CB CD34(+) cells would induce differentiation and survival of monocytes and osteoclasts in vitro and in vivo. METHODS: Human M-CSF was overexpressed in cord blood CD34(+)  cells using a lentiviral vector. RESULTS: We show that LV-hM-CSF-transduced CB CD34(+) cells expand 3.6 and 8.5 fold more with one or two exposures to the hM-CSF expressing vector, respectively, when compared to control cells...
February 3, 2017: European Journal of Haematology
Manal Alsheikh, Ahmad Abu-Khader, Matthew Michalicka, Roya Pasha, Nicolas Pineault
BACKGROUND: Osteoblasts possess strong growth modulatory activity on hematopoietic stem cells and progenitors. We sought to characterise the growth and differentiation modulatory activities of human osteoblasts at distinct stages of maturation on cord blood (CB) progenitors in the context of osteoblast conditioned medium (OCM). METHODS: OCM was produced from MSC-derived osteoblasts (M-OST) at distinct stages of maturation. The growth modulatory activities of the OCM were tested on CB CD34(+) cells using different functional assays...
February 3, 2017: European Journal of Haematology
Oded Gilad, Orna Steinberg Shemer, Michal Nevo, Orly Dgany, Tanya Krasnov, Sharon Noy-Lotan, Ron Rabinowicz, Nofar Amitai, Shifra Ben-Dor, Isaac Yaniv, Joanne Yacobovich, Hannah Tamary
OBJECTIVE: α-Thalassemia, one of the most common genetic diseases, is caused by deletions or point mutations affecting one to four α-globin genes. Molecular diagnosis is important to prevent the most severe forms of the disease. However, the diagnosis of α-thalassemia is complex due to a high variability of the genetic defects involved, with over 250 described mutations. We summarize herein the findings of genetic analyses of DNA samples referred to our laboratory for the molecular diagnosis of α-thalassemia, along with a detailed clinical description...
February 3, 2017: European Journal of Haematology
Joanna M Davies, Thomas R Osborne, Polly M Edmonds, Steve A Schey, Steve Devereux, Irene J Higginson, Christina Ramsenthaler
OBJECTIVES: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients. METHODS: Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated...
February 3, 2017: European Journal of Haematology
Vladimir Lazarevic, Aldana Rosso, Gunnar Juliusson, Petar Antunovic, Åsa Rangert Derolf, Stefan Deneberg, Lars Möllgård, Bertil Uggla, Lovisa Wennström, Anders Wahlin, Martin Höglund, Sören Lehmann, Bertil Johansson
To ascertain the incidence/clinical implications of isolated autosomal trisomies in adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry RESULTS: Of the 3,179 cytogenetically informative AMLs diagnosed January 1997 - May 2015, 246 (7.7%) had isolated trisomies. The frequency increased by age (2.4% at age 18-60 years vs. 23% at >60 years; P < 0.0001); the median age was 69 years. The five most common were +8 (4.0%), +13 (0.9%), +11 (0.8%), +21 (0.7%), and +4 (0...
February 2, 2017: European Journal of Haematology
Masaaki Sekine, Yoko Kubuki, Takuro Kameda, Masaki Takeuchi, Takanori Toyama, Noriaki Kawano, Kouichi Maeda, Seiichi Sato, Junzo Ishizaki, Hiroshi Kawano, Ayako Kamiunten, Keiichi Akizuki, Yuki Tahira, Haruko Shimoda, Kotaro Shide, Tomonori Hidaka, Akira Kitanaka, Kiyoshi Yamashita, Hitoshi Matsuoka, Kazuya Shimoda
OBJECTIVE: The efficacy of mogamulizumab in ATLL was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. METHOD: We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. RESULTS: Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab...
February 2, 2017: European Journal of Haematology
Swapna Thota, Anjali Advani
Despite an improved understanding of disease biology and the use of multi-agent chemotherapy, the long-term survival of adults with B-cell acute lymphoblastic leukemia (B-ALL) ranges from 35-50%. Management of patients with relapsed B-ALL, a group characterized by dismal outcomes, poses a clinical challenge. To address this unmet need, novel therapeutics are being investigated in the setting of relapsed B-ALL with encouraging results. CD22 is an important B-cell antigen expressed in 80-90% of B-ALL cases. CD22 undergoes constitutive endocytosis with antibody ligation, making it an attractive biologic target for immunoconjugates...
February 2, 2017: European Journal of Haematology
D Heidenreich, S Kreil, F Nolte, W-K Hofmann, T Miethke, S A Klein
OBJECTIVE: Multidrug-resistant organisms (MDRO) are a challenge in allogeneic hematopoietic cell transplantation (HCT). However, in the literature there is no comprehensive analysis on MDRO in HCT. In this retrospective, single center analysis, we appraised prevalence and clinical impact of MDRO in 98 consecutive allogeneic HCT patients. METHOD: Prior to the conditioning (baseline) and whenever clinically indicated patients underwent a full screening for MDRO (stool and urine cultures, swabs from several body regions)...
January 30, 2017: European Journal of Haematology
A D de Jongh, E J van Beers, K M K de Vooght, R E G Schutgens
BACKGROUND: The dramatic impact of hemosiderosis on survival in chronically transfused patients with hereditary anaemia is well known. We evaluated whether patients receiving multiple red blood-cell (RBC) transfusions are adequately screened for hemosiderosis. METHODS: We retrospectively assessed hemosiderosis screening and prevalence in adult patients that received over twenty RBC units in the University Medical Centre Utrecht from 2010 till 2015. Hemosiderosis was defined as ferritin ≥1000μg/L...
January 27, 2017: European Journal of Haematology
Naoki Mori, Mari Ohwashi-Miyazaki, Kentaro Yoshinaga, Michiko Okada, Masayuki Shiseki, Toshiko Motoji, Junji Tanaka
OBJECTIVES: We previously reported loss of heterozygosity on 1p in chronic myelogenous leukemia (CML). We analyzed promoter methylation and mutation of tumor suppressor genes on 1p36 in CML. METHODS: We performed methylation specific PCR (MS-PCR) analysis of the PRDM2, RUNX3, and TP73 genes in 61 patients with CML (43 chronic phase, CP; 2 accelerated phase; and 16 blast crisis, BC). Oxidative MS-PCR, PCR-single strand conformation polymorphism, and real time reverse transcriptase-PCR were also analyzed...
January 27, 2017: European Journal of Haematology
Keisuke Kawamoto, Hiroaki Miyoshi, Eriko Yanagida, Noriaki Yoshida, Junichi Kiyasu, Yasuji Kozai, Tatsuma Morikita, Takeharu Kato, Hitoshi Suzushima, Shinobu Tamura, Tsuyoshi Muta, Koji Kato, Tetsuya Eto, Ritsuko Seki, Koji Nagafuji, Hirohito Sone, Jun Takizawa, Masao Seto, Koichi Ohshima
OBJECTIVES: T-cell prolymphocytic leukemia (T-PLL) is a very rare, aggressive T-cell neoplasm. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is also a highly aggressive lymphoma. These two diseases can often be confused with each other; therefore, we aimed to determine the clinical and pathological differences between T-PLL and PTCL, NOS. METHODS: We analyzed 15 T-PLL and 91 PTCL, NOS patients, and also compared clinical features between T-PLL and PTCL-NOS with leukemic presentation...
January 27, 2017: European Journal of Haematology
Xiao-Hui Zhang, Jia-Min Zhang, Wei Han, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yuan-Yuan Zhang, Xiao-Dong Mo, Yao Chen, Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang
OBJECTIVE: To retrospectively identify characteristics and risk factors of viral encephalitis (VE) in patients who underwent a haplo-identical hematopoietic stem cell transplant (HSCT). METHODS: A nested case-control study was designed. Cases with VE and controls were identified from a cohort composed of 1274 patients who underwent a haplo-identical HSCT from 2012 to 2015. RESULTS: VE was identified in 30 patients (2.4%).The median time from HSCT to diagnosis was 144...
January 27, 2017: European Journal of Haematology
X Cahu, M Carré, C Recher, A Pigneux, M Hunault-Berger, N Vey, P Chevallier, J Delaunay, E Gyan, B Lioure, C Bonmati, C Himberlin, Y Hichri, G Guillerm, D Bouscary, F Larosa, M Ojeda-Uribe, M Bernard, M C Béné, N Ifrah, J Y Cahn
OBJECTIVES: anthracyclins and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body surface area (BSA) on patients' characteristics, physicians' strategy, dose adjustment and clinical outcome. METHODS: The GOELAMS 2001 phase III trial included 823 AML patients below 60 years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered...
January 25, 2017: European Journal of Haematology
Roni Shouval, Sharon Katz, Arnon Nagler, Drorit Merkel, Ilan Ben-Zvi, Shlomo Segev, Yechezkel Sidi, Ilan Goldenberg, Shaye Kivity, Elad Maor
BACKGROUND: Data on the functional impact of anemia on cardiorespiratory fitness (CRF) and survival in healthy individuals are limited. Our aim was to evaluate the association between anemia thresholds, low CRF and survival in an otherwise healthy adults. METHODS: Study population included 16,334 apparently healthy subjects attending annual periodic health screening examinations (71,200 annual visits), including exercise stress testing (EST). Anemia was defined by the World Health Organization (WHO) or Beutler and Waalens' (BW) criteria...
January 25, 2017: European Journal of Haematology
Oscar M Pello, Andrew Innes, Anne Bradshaw, Sally-Anne Finn, Shab Uddin, Emma Bray, Eduardo Olavarria, Jane F Apperley, Jiri Pavlu
BACKGROUND: Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T-cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low frequency T-cells such as BKV-specific T-cells. CASE REPORT: Here we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy...
January 13, 2017: European Journal of Haematology
Beenu Thakral, L Jeffrey Medeiros, Parth Desai, Pei Lin, C Cameron Yin, Guilin Tang, Joseph D Khoury, Shimin Hu, Jie Xu, Sanam Loghavi, Bei Hu, Yasuhiro Oki, Shaoying Li
OBJECTIVES: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) represents 5%-10% of all DLBCL cases, which has been associated with a poorer prognosis in patients treated with R-CHOP. Prognostic impact of CD5 expression in patients with DLBCL treated with R-EPOCH has not been evaluated. METHODS: We studied 130 patients with de novo DLBCL who received frontline R-EPOCH therapy. The clinicopathologic features and overall survival (OS) were compared between patients with CD5+ and CD5- DLBCL...
December 31, 2016: European Journal of Haematology
Gunnar Larfors, Fredrik Sandin, Johan Richter, Anders Själander, Leif Stenke, Mats Lambe, Martin Höglund
PURPOSE: To evaluate the influence of socioeconomic variables on treatment selection and survival of patients with chronic myeloid leukaemia (CML). METHODS: Using information available in population-based Swedish registries we evaluated indices of health, education and economy from the 980 patients in the Swedish CML register diagnosed between 2002 and 2012. Apart from internal comparisons, five age-, gender- and region-matched control subjects per patient served as control cohort...
December 23, 2016: European Journal of Haematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"